Literature DB >> 31678160

Epidemiology and pathogenesis of maternal-fetal transmission of Trypanosoma cruzi and a case for vaccine development against congenital Chagas disease.

Lizette Rios1, E Emanuel Campos2, Ramkumar Menon3, M Paola Zago4, Nisha J Garg5.   

Abstract

Trypanos o ma cruzi (T. cruzi or Tc) is the causative agent of Chagas disease (CD). It is common for patients to suffer from non-specific symptoms or be clinically asymptomatic with acute and chronic conditions acquired through various routes of transmission. The expecting women and their fetuses are vulnerable to congenital transmission of Tc. Pregnant women face formidable health challenges because the frontline antiparasitic drugs, benznidazole and nifurtimox, are contraindicated during pregnancy. However, it is worthwhile to highlight that newborns can be cured if they are diagnosed and given treatment in a timely manner. In this review, we discuss the pathogenesis of maternal-fetal transmission of Tc and provide a justification for the investment in the development of vaccines against congenital CD.
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Chagas; Congenital; Maternal-fetal transmission; Trypanosoma cruzi; Vaccine

Mesh:

Substances:

Year:  2019        PMID: 31678160      PMCID: PMC6954953          DOI: 10.1016/j.bbadis.2019.165591

Source DB:  PubMed          Journal:  Biochim Biophys Acta Mol Basis Dis        ISSN: 0925-4439            Impact factor:   5.187


  7 in total

Review 1.  Oxidative stress implications for therapeutic vaccine development against Chagas disease.

Authors:  Subhadip Choudhuri; Lizette Rios; Juan Carlos Vázquez-Chagoyán; Nisha Jain Garg
Journal:  Expert Rev Vaccines       Date:  2021-08-30       Impact factor: 5.217

Review 2.  Potential Role of Antioxidants as Adjunctive Therapy in Chagas Disease.

Authors:  Juana P Sánchez-Villamil; Paula K Bautista-Niño; Norma C Serrano; Melvin Y Rincon; Nisha J Garg
Journal:  Oxid Med Cell Longev       Date:  2020-03-26       Impact factor: 6.543

3.  Cruzipain and Its Physiological Inhibitor, Chagasin, as a DNA-Based Therapeutic Vaccine Against Trypanosoma cruzi.

Authors:  Natacha Cerny; Augusto Ernesto Bivona; Andrés Sanchez Alberti; Sebastián Nicolás Trinitario; Celina Morales; Alejandro Cardoso Landaburu; Silvia Inés Cazorla; Emilio Luis Malchiodi
Journal:  Front Immunol       Date:  2020-10-09       Impact factor: 7.561

4.  Experimental Nanovaccine Offers Protection Against Repeat Exposures to Trypanosoma cruzi Through Activation of Polyfunctional T Cell Response.

Authors:  Imran H Chowdhury; Nandadeva Lokugamage; Nisha Jain Garg
Journal:  Front Immunol       Date:  2020-12-22       Impact factor: 7.561

Review 5.  Infections at the maternal-fetal interface: an overview of pathogenesis and defence.

Authors:  Christina J Megli; Carolyn B Coyne
Journal:  Nat Rev Microbiol       Date:  2021-08-25       Impact factor: 60.633

6.  Trypanosoma cruzi Induces the PARP1/AP-1 Pathway for Upregulation of Metalloproteinases and Transforming Growth Factor β in Macrophages: Role in Cardiac Fibroblast Differentiation and Fibrosis in Chagas Disease.

Authors:  Subhadip Choudhuri; Nisha Jain Garg
Journal:  mBio       Date:  2020-11-10       Impact factor: 7.867

7.  Prognostic Performance of Peripheral Blood Biomarkers in Identifying Seropositive Individuals at Risk of Developing Clinically Symptomatic Chagas Cardiomyopathy.

Authors:  Subhadip Choudhuri; Suresh K Bhavnani; Weibin Zhang; Valentina Botelli; Natalia Barrientos; Facundo Iñiguez; Maria Paola Zago; Nisha Jain Garg
Journal:  Microbiol Spectr       Date:  2021-08-25
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.